Symptomatic Accessory Great Saphenous Vein Reflux When Conservative Therapy Has Not Controlled Symptoms

In adults with chronic venous insufficiency, reflux in the accessory great saphenous vein can sustain symptoms even when conservative measures have been applied. When that first-line approach fails to achieve adequate leg symptom control, a structured next-step protocol applies.

Prior line — escalation criteria

Conservative therapy — comprising compression therapy, venotonic medications, lifestyle modifications, and weight loss where applicable — did not achieve the goals of reduced leg discomfort and reduced edema volume. Persistent symptomatic accessory GSV reflux under these conditions is the clinical trigger for escalation.

Clinical scenario

Adults with confirmed symptomatic accessory great saphenous vein reflux who remain symptomatic after an adequate trial of conservative management.

Next-step approach (partial overview)

The recommended approach for this situation involves an ablative procedure directed at the accessory great saphenous vein, combined with continued supportive care. The specific modalities, procedural considerations, and full management sequence are detailed in the structured regimen.

Treatment goals

Shorter time to ulcer healing where applicable, symptom improvement of at least 2.1 points on the Venous Clinical Severity Score, and a reduced rate of ulcer recurrence at two years.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jscai.2025.103729

For patients with symptomatic accessory GSV reflux, the SCAI guideline panel suggests ablation therapy plus conservative management rather than conservative management alone (conditional recommendation, very low certainty of evidence).

When accessory veins are associated with pathology such as ulcers or other symptoms, patients may reasonably choose ablation therapy.

As with GSV reflux with or without SSV reflux, the data from the included studies indicate that ablation therapy probably reduces median days to ulcer healing (MD, 31.73 fewer days; 95% CI, 45.1-18.3).

Ablation therapy may also reduce the rate of ulcer recurrence at 2 years (RR, 0.39; 95% CI, 0.18-0.81), lead to symptom improvement (VCSS MD, 2.1 lower; 95% CI, 2.99-1.21), and improve QoL (EQ-ED-5L MD, 1.3 higher; 95% CI, 2.1-4.8).

View source ↗